1 RISK-BASED APPROACH TO PHARMACEUTICAL DEVELOPMENT

In the United States, the U.S. Food and Drug Administration (FDA) ensures the quality of drug products using a two-pronged approach involving review of information submitted in applications as well as inspection of manufacturing facilities for conformance to requirements for current good manufacturing practice
OVERVIEW OF RISK-BASED APPROACH TO PHASE APPROPRIATE VALIDATION

(cGMP). In 2002, the FDA, together with the global community, implemented a new initiative, “Pharmaceutical Quality for the 21st Century: A Risk-Based Approach” to evaluate and update current programs based on the following goals:

- The most up-to-date concepts of risk management and quality system approaches are incorporated while continuing to ensure product quality.
- The latest scientific advances in pharmaceutical manufacturing and technology are encouraged.
- The submission review program and the inspection program operate in a coordinated and synergistic manner.
- Regulatory and manufacturing standards are applied consistently.
- FDA resources are used most effectively and efficiently to address the most significant issues.

In the area of analytical method validation and instrument performance qualification, principles and risk-based orientation, and science-based policies and standards, are the ultimate driving forces in a risk-based approach to these activities.

1. **Risk-based orientation.** To comply with the new guiding regulatory principle to provide the most effective public health protection, regulatory agencies and pharmaceutical companies must match their level of effort against the magnitude of risk. Resource limitations prevent uniform intensive coverage of all pharmaceutical products and production.

2. **Science-based policies and standards.** Significant advances in the pharmaceutical sciences and in manufacturing technologies have occurred over the last two decades. Although this knowledge has been incorporated in an ongoing manner, the fundamental nature of the changes dictates a thorough evaluation of the science base to ensure that product quality regulation not only incorporates up-to-date science but also encourages further advances in technology. Recent science can also contribute significantly to assessment of risk.

Related directly or indirectly to implementation of the risk-based approach to pharmaceutical quality, the following guidance affecting the analytical method and instrument qualification had been either initiated or implemented.

**FDA 21 Code of Federal Regulations (CFR) Part 11: Electronic Records Requirements.** The final guidance for industry Part 11, Electronic Records, Electronic Signatures: Scope and Application, clarifies the scope and application of the Part 11 regulation and provides for enforcement discretion in certain areas. The guidance explains the goals of this initiative, removes
barriers to scientific and technological advances, and encourages the use of risk-based approaches.

*ICH (International Conference on Harmonization) Q9: Risk Management.* The goal of the guidance is to manage risk to patients, based on science, from information on the product, process, and facility. The level of oversight required is commensurate with the level of risk to patients and the depth of product and process understanding.

*FDA Guidance for Industry PAT: A Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance.* This guidance is intended to encourage the voluntary development and implementation of innovative pharmaceutical manufacturing and quality assurance technologies. The scientific, risk-based framework outlined in this guidance, process analytical technology (PAT), helps pharmaceutical manufacturers design, develop, and implement new and efficient tools for use during product manufacture and quality assurance while maintaining or improving the current level of product quality assurance. It also alleviates any concerns that manufacturers may have regarding the introduction and implementation of new manufacturing technologies.

*FDA Guidance for Industry: Quality Systems Approach to Pharmaceutical cGMP Regulations.* One of the objectives of this guidance is to provide a framework for implementing quality by design, continual improvement, and risk management in the drug manufacturing process.

*FDA Guidance for Industry INDs: cGMP for Phase 1 Investigational Drugs.* This guidance recommended that sponsors and producers of phase 1 material consider carefully risks in the production environment that might adversely affect the resulting quality of an investigational drug product.

Implementation of a risk-based approach to analytical method validation and performance verification should be done simultaneously and not in isolation. It is only through a well-thought-out plan on the overall laboratory system of instrument performance verification that quality data for analytical method validation will be obtained. The laboratory will subsequently be able to support the manufacture of either clinical trial materials or pharmaceutical products for patients. Details of risk-based approaches to phase appropriate analytical method validation and performance verification are presented in subsequent chapters.

## 2 REGULATORY REQUIREMENTS FOR PERFORMANCE VERIFICATION OF INSTRUMENTS

System validation requirements are specified in many different sources, including 21 CFR Part 58 [good laboratory practice (GLP)], 21 CFR Parts 210 and 211 (cGMP) [1], and more recently, in the GAMP 4 guide [2]. GLP, and GMP/cGMP are often summarized using the acronym GXP. Current GXP regulations require
that analytical instruments be qualified to demonstrate suitability for the intended use. Despite the fact that instrument qualification is not a new concept and regulated firms invest a lot of effort, qualification-related deviations are frequently cited in inspectional observations and in warning letters by regulatory agencies such as the FDA and its equivalents in other countries. In common terms, the objective of qualification is to establish documented evidence that a system has been designed and installed according to specifications and operates in such a way that it fulfills its intended purpose.

GLP makes the following provisions in 21 CFR 58.63 about maintaining, calibrating, and testing equipment:

• Equipment is to be adequately inspected, cleaned, maintained, calibrated, and tested.
• Written standard operating procedures (SOPs) are required for testing, calibration, and maintenance.
• Written records are to be maintained for all inspection, maintenance, calibration, and testing.

cGMP makes the following provisions in 21 CFR 211.68(a):

• Automatic equipment, including computers, that will perform a function satisfactorily may be used.
• Equipment is to be calibrated, inspected, or checked routinely according to a written program designed to assure proper performance.
• Written records of calibration checks and inspections are to be maintained.

Many validation professionals in regulated firms are not sure what exactly to qualify or requalify, test, and document. How much testing is enough? Unlike analytical method validation, there were no clear standards for equipment qualification. The United States Pharmacopeia (USP) has addressed this issue by publishing General Chapter 1058 on analytical instrument qualification (AIQ) [3,4]. The USP establishes AIQ as the basis for data quality and defines the relationship to analytical method validation, system suitability testing, and quality control checks. Similar to analytical method validation, the intent of AIQ is to ensure the quality of an instrument before conducting any tests. In contrast, system suitability and quality control checks ensure the quality of analytical results right before or during sample analyses.

3 GENERAL APPROACH TO INSTRUMENT PERFORMANCE QUALIFICATION

Testing is one of the most important analytical measures for system developers and system users when verifying that a system fulfills the defined system requirements and is fit for the intended purpose. Generally, the fitness of systems for the
intended purpose (i.e., their quality) needs to be ensured through constructive and analytical measures. Constructive measures are defined in terms of recognized professional engineering practices and include formal design methodologies that typically follow a life-cycle approach. System qualification follows a structured approach that uses test cases and test parameters based on a scientific and risk-based analysis. Defining and executing these tests typically require the use of metrology.

Other analytical measures include trending analysis of metrics such as error rates, formal methods of failure analysis, and formal reviews and inspections. Testing and the associated collection of documented evidence on the system test activities are key tasks of quality assurance. The documented evidence comprises test planning, test execution, test cases, and test results, all of which must be traceable to the requirements documented in various levels of specification documents (i.e., user requirements specification, functional specifications, design specifications, test specifications, etc.).

3.1 Definition of Terms

Many different definitions are used for the relevant terms in the area of equipment qualification. Not all of them are identical. For the sake of this chapter, we use the terms *design qualification* (DQ), *installation qualification* (IQ), *operational qualification* (OQ), and *performance qualification* (PQ), in line with the definitions originally published by the Valid Analytical Measurement Instrument Working Group (see Figure 1). Similar system qualification approaches are discussed thoroughly in GAMP (Good Automated Manufacturing Practice) Forum publications and in USP General Chapter 1058. DQ, IQ, OQ, and PQ constitute important phases that result in key deliverables during the overall validation activities necessary over a system’s life cycle (see Figure 2).

**Design Qualification** During DQ, the functional and operational specifications of an instrument need to be defined and documented. DQ is an important decision-making tool for selecting the best system and supplier. The right type of equipment is selected for specific tasks, and the supplier’s ability to meet and reproduce these performance criteria consistently through appropriate quality processes in design, development, manufacturing, and support is crucial for efficacy and risk mitigation. DQ is primarily the user’s responsibility, because this is the only logical place to define site requirements. The supplier, however, typically needs to provide materials such as technical specifications and other documents relevant to system validation. This includes evidence on processes that are critical to quality, including the life-cycle methodology. DQ focuses on specifications, design documentation, requirements traceability from design to test, corrective action procedures, impact analyses, test plans, and test evidence. DQ responds to a requirement originally defined in GLP (21 CFR Part 58.61) that mandates that appropriate design and adequate capacity for consistent functioning as intended are assured for equipment used in activities subject to this regulation.
**OVERVIEW OF RISK-BASED APPROACH TO PHASE APPROPRIATE VALIDATION**

**FIGURE 1** The four stages of instrument qualification and definition of terms according to the Valid Analytical Measurement Instrument Working Group. (From [5].)

*Installation Qualification*  IQ uses procedures that demonstrate, to a high degree of assurance, that an instrument or system has been installed according to accepted standards. IQ provides written evidence that the system has been installed according to the specifications defined by the manufacturer (supplier) and, if applicable, the user’s organization. IQ checks the correctness of the installation and documents the intactness of the system, typically through system inventory lists, part numbers, firmware revisions, system drawings, and wiring and plumbing diagrams. Several organizations have provided specific guidance about the scope of an IQ and elaborated on the potential division of responsibilities between the system supplier and the user’s organization. One important conclusion is that assembly checks performed at the supplier’s factory...
cannot be substituted for an IQ performed at the user’s site [6]. The supplier’s documented test results (e.g., factory acceptance tests), however, can be used to reduce the extent of validation activities performed during an IQ. The key is that IQ demonstrates and documents that the system has been received and installed in the user’s domain according to the relevant specifications.

The IQ is usually provided by the vendor at a cost. The typical deliverables include the following information:

- System location
- Equipment model/serial numbers
- Documentation of basic function and safety features
- Documentation about compliance with site requirements

**Operational Qualification** In contrast to an IQ, which challenges the installation process, operational qualification focuses on the functionality of the system. An OQ challenges key operational parameters and, if required, security functions by running a well-defined suite of functional tests. The OQ uses procedures that demonstrate, to a high degree of assurance, that an instrument or system is operating according to accepted standards. In most cases, the OQ is delivered as a paid service from the provider. It typically includes a suite of component and system tests that are designed to challenge the functional aspects of the system. The OQ deliverable needs to provide documented and auditable evidence of control. The frequency of the OQ is determined by the user’s organization. In most laboratories, the typical frequency is once or twice a year after the initial OQ.
OVERVIEW OF RISK-BASED APPROACH TO PHASE APPROPRIATE VALIDATION

Performance Qualification and Performance Verification The terms performance qualification (PQ) and performance verification (PV) are used as synonyms. PQ verifies system performance under normal operating conditions across the anticipated operating range of the equipment. This makes PQ mostly an application-specific test with application-specific acceptance limits. For chromatography equipment, ongoing verification of system performance includes system suitability tests, as defined in General Chapter 621 on chromatography of the USP [7], which outlines the apparatus tests as well as the calculation formulas to be used for quantification and the evaluation of system suitability. The European and Japanese pharmacopeias use a similar approach, but there are regional differences in how certain system suitability parameters have to be calculated. In the following chapters we focus on the holistic and modular tests required for operational qualification but do not elaborate in detail on application-specific performance qualification.

Requalification After Repair (RQ) In essence, RQ is similar to OQ. RQ’s goal is to verify the correctness and success of a repair procedure performed on a system, and to put the system back into the original qualified state by running a series of appropriate tests. RQ typically is a subset of an OQ, but for complex repairs to components that are critical to the overall performance of the system, it may be necessary to perform the complete suite of OQ tests.

3.2 Analytical Instrument Qualification: USP 1058

USP General Chapter 1058 is a step forward for the validation community [8]. It establishes the well-proven 4Q model as the standard for instrument qualification and provides useful definitions of roles, responsibilities, and terminology to steer the qualification-related activities of regulated firms and their suppliers. The 4 Qs in the model refer to DQ, IQ, OQ, and PQ (see Figure 3). The 4Q model helps answer the following critical questions:

- How can an analytical laboratory prove that a given analysis result is based on trustworthy and reliable instrument data?
- How can the analytical laboratory ascertain the validity of the analysis result and show appropriate evidence that the analytical instrument was really doing what the analyst thought it would do and that the instrument was within the specifications required for the analysis?

The AIQ chapter of the USP categorizes the rigor and extent of the qualification activities by instrument class. As an example, gas chromatographs are categorized as class C (complex instruments with highly method-specific conformance requirements). The acceptance limits (conformity bounds) are determined by the application. The deployment (installation and qualification) of such an instrument is complicated and typically requires assistance from specialists. In any case, USP 1058 class C instruments are required to undergo a full
3.3 Recommendations for Analytical Instrument Qualification

1. Develop an SOP for AIQ according to the 4Q qualification model.
2. If you already have an SOP for AIQ, determine how it can be mapped to the 4Q model.
3. If your SOP proposes a different methodology than that of 4Q, you need to come up with a scientifically sound rationale. Document your rationale and explain how your methodology ensures trustworthy, reliable, and consistent instrument data.
OVERVIEW OF RISK-BASED APPROACH TO PHASE APPROPRIATE VALIDATION

4. Use a single procedure for an instrument category, independent of the vendor and the location. Acceptance criteria may have to vary by make, model, and intended application.

5. Assess which instruments are used for regulated activities and whether the data generated by the instrument are subject to a predicate rule.

6. Assess the risk of instrument failure or nonconformance, using scientific knowledge.

7. Define qualification protocols for the various instrument classes in your lab. If necessary and appropriate, work with your instrument suppliers or partner with someone who has a proven track record in the field of instrument qualification services.

8. The USP guidance is general regarding the use and impact of data systems. Therefore, plan additional qualification and acceptance tests to obtain a high degree of assurance that control, communication, and data are accurate and reliable. Your integrated validation and qualification approach needs to consider the system as a whole, including the data system.

REFERENCES


7. U.S. Pharmacopeia, General Chapter ⟨621⟩, Chromatography. USP, Rockville, MD.